Arkansas alleges insulin pricing plot involving Novo Nordisk, Eli Lilly and Sanofi
Arkansas Attorney General Leslie Rutledge has filed a complaint alleging that the insulin makers have colluded with a group of pharmacy benefit managers, including Express Scripts, to raise insulin prices and pay back the PBMs in discounts.
by andreas lønstrup, translated by daniel pedersen
The State of Arkansas has filed a complaint against Novo Nordisk, Eli Lilly, and Sanofi – all makers of the insulin supplying the state – as well as a group of pharmacy benefit managers (PBMs) that dominate the insulin pricing system there, including Express Scripts, which is the biggest PBM in the US.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
US House of Representatives passes bill to cap insulin price
For subscribers
.jpg)
.jpg&w=384&q=75)
